InnoPharmax Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
InnoPharmax has a total shareholder equity of NT$433.7M and total debt of NT$10.0M, which brings its debt-to-equity ratio to 2.3%. Its total assets and total liabilities are NT$478.1M and NT$44.4M respectively.
Belangrijke informatie
2.3%
Verhouding schuld/eigen vermogen
NT$10.00m
Schuld
| Rente dekkingsratio | n/a |
| Contant | NT$118.10m |
| Aandelen | NT$433.70m |
| Totaal verplichtingen | NT$44.37m |
| Totaal activa | NT$478.07m |
Recente financiële gezondheidsupdates
Analyse van de financiële positie
Kortlopende schulden: 4172's short term assets (NT$157.3M) exceed its short term liabilities (NT$41.3M).
Langlopende schulden: 4172's short term assets (NT$157.3M) exceed its long term liabilities (NT$3.1M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 4172 has more cash than its total debt.
Schuld verminderen: 4172's debt to equity ratio has reduced from 8.6% to 2.3% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: 4172 has sufficient cash runway for more than a year based on its current free cash flow.
Voorspelling contante baan: 4172 has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 2.7% each year.